問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Linkou Chang Gung Medical Foundation (在職)

Division of Urology

更新時間：2023-09-19

謝明里Hsieh, Ming-Li
  • Principal Investigator
  • Clinical Trial Experience (year) 23 years 9 個月

Recruiting Trial

4Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

謝明里

List

10Cases

2007-11-01 - 2009-03-01

Phase II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Terminated7Sites

2023-03-20 - 2030-06-30

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2021-08-01 - 2028-01-30

Phase III

Active
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer

  • Condition/Disease

    Metastatic Castration-Resistant Prostate Cancer (mCRPC)

  • Test Drug

    膠囊劑

Participate Sites
6Sites

Recruiting6Sites

2009-12-01 - 2013-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
12Sites

Terminated12Sites

2010-11-01 - 2018-06-30

Others

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2009-09-30 - 2021-10-18

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2022-01-01 - 2025-12-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting2Sites

2021-06-01 - 2022-05-30

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2021-08-01 - 2028-01-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Not yet recruiting4Sites

Recruiting3Sites

2013-08-01 - 2017-12-31

Phase III

A Randomized, Double-blind, Parallel Group Study to Compare the Efficacy and Safety of Combination Treatment With Dutasteride (0.5mg) and Tamsulosin (0.2mg) With Tamsulosin (0.2mg) Monotherapy, Administered Once Daily for 2 Years, on the Improvement of Symptoms and Health Outcomes in Men With Moderate to Severe Benign Prostatic Hyperplasia

  • Condition/Disease

    Moderate to Severe Benign Prostatic Hyperplasia

  • Test Drug

    (1) AVODART SOFT CAPSULES；(2) Harnalidge D tablets

Participate Sites
8Sites

Not yet recruiting1Sites

Terminated7Sites

鄭鴻琳
National Taiwan University Hospital

Division of Urology

聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB